Last reviewed · How we verify
REGENECYTE
REGENECYTE is a cell therapy that uses expanded autologous bone marrow-derived stem cells to promote tissue regeneration and repair.
REGENECYTE is a cell therapy that uses expanded autologous bone marrow-derived stem cells to promote tissue regeneration and repair. Used for Chronic heart failure, Myocardial infarction.
At a glance
| Generic name | REGENECYTE |
|---|---|
| Sponsor | StemCyte, Inc. |
| Drug class | Autologous cell therapy |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
The drug involves harvesting a patient's own bone marrow stem cells, expanding them ex vivo, and reinfusing them to stimulate regenerative processes in damaged tissues. The mechanism relies on the immunomodulatory and paracrine effects of mesenchymal stem cells, which secrete growth factors and cytokines that promote angiogenesis, reduce inflammation, and support tissue healing.
Approved indications
- Chronic heart failure
- Myocardial infarction
Common side effects
- Injection site reactions
- Fever
- Transient elevation of inflammatory markers
Key clinical trials
- Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
- A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition (PHASE3)
- Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |